Advertisement

The Design of a Radiolabeled Monoclonal Antibody for Radioimmunodiagnosis and Radioimmunotherapy

  • S. J. DeNardo
  • G. L. DeNardo
  • S. V. Deshpande
  • G. P. Adams
  • D. J. Macey
  • S. L. Mills
  • A. L. Epstein
  • C. F. Meares
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 152)

Abstract

Monoclonal antibodies have become recognized as promising carrier molecules for the development of target specific radiopharmaceuticals. Since the hybridoma technology can be used to discriminate small epitopes on products of either normal or abnormal cells and to produce antibodies which react uniquely with those epitopes, a new generation of biologic targets are being sought on hormones, hormone precursors, myosin, fibrin, blood cells, infectious agents, tumor cells, tumor associated antigen products and so forth. Although critical for ultimate imaging and therapeutic success, epitope recognition and appropriate target selection is only the first step toward immunologically derived radiopharmaceuticals.

Keywords

Blood Clearance Liver Uptake Indium Chloride High Molecular Weight Material Molecular Sieve Chromatography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. J. DeNardo, J. A. Jungerman, G. L. DeNardo, M.C. Lagunas-Solar, W. C. Cole, C. F. Meares, The Choice of radionuclides for radioimmunotherapy, in: “Developmental Role of Short-Lived Radionuclides in Nuclear Medicine Practice,” J.W. Theissen and P. Paras (eds.),DOE symposium Series, Washington, D.C., May 3–5, 1982, Oak Ridge, Tennessee, Department of Energy Technical Information Center, CONF-820523, NTIS, pp. 399–412.Google Scholar
  2. 2.
    S. E. Halpern, P. L. Stern, P. L. Hagan, A. Chen, G. S. David, W. J. Desmond, T. H. Adams, R. M. Bartholomew, J. M. Frincke, C. E. Brautigam, Radiolabeling of monoclonal antitumor antibodies: Comparison of I-125 and 111-In anti-CEA with Ga-67 in nude mouse human tumor model, Clin. Nuc. Med. 6:453 (1981) (Abstract).CrossRefGoogle Scholar
  3. 3.
    B. A. Khaw, T. Edginton, H. W. Strauss, Differences in experimental tumor localization of dual labeled monoclonal antibody, J. Nuc. Med. 27:1293–1299 (1986).Google Scholar
  4. 4.
    C. F. Meares. Use of bifunctional chelating agents for radiolabeling antibodies. This book, pp.Google Scholar
  5. 5.
    W. C. Cole, S. J. DeNardo, C. F. Meares, M. J. McCall, G. L. DeNardo, A. L. Epstein, H. A. O’Brien, M. K. Moi, Comparative serum stability of radiochelates for antibody radiopharmaceuticals, J. Nuc. Med. 28:83–89 (1987).Google Scholar
  6. 6.
    S. E. Halpern, P. L. Hagan, P. R. Garver, J. A. Koziol, A. W. N. Chen, J. M. Frincke, R. M. Bartholomew, G. S. David, T. H. Adams, Stability, characterization and kinetics of 111-In labeled monoclonal anti-tumor antibodies in normal animals and nude mouse human tumor models, Cancer Res. 43:5347–5355 (1983).PubMedGoogle Scholar
  7. 7.
    G. L. DeNardo, S. J. DeNardo, D. J. Macey, S. L. Mills, Quantitative pharmacokinetics of radiolabeled antibodies for imaging and therapy in patients. This book, pp.Google Scholar
  8. 8.
    J. L. Murray, M. G. Rosenblum, R. E. Sobol, R. M. Bartholomew, C. E. Plager, T. P. Haynie, M. F. Johns, H. J. Glenn, L. Lambi, R. S. Benjamin, N. Papadopoulos, A. W. Boddie, J. M. Frincke, G. S. David, D. J. Carlo, E. M. Hersh, Radioimmunoimaging in malignant melanoma with In-111 labeled monoclonal Ab 96.5, Cancer Res. 45:2376–2381 (1985).PubMedGoogle Scholar
  9. 9.
    S. J. DeNardo, J-B. Peng, G. L. DeNardo, S. L. Mills, A. L. Epstein, Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development, Nuc. Med. Biol. 13:303–310 (1986).Google Scholar
  10. 10.
    A. L. Epstein, M. W. Herman, H. Kim, R. F. Dorfman, H. S. Kaplan, Biology of the human malignant lymphomas. III: Intracranial heterotransplantation on nude athymic mouse, Cancer 37:2158–2176 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    A. L. Epstein, R. J. Marder, J. N. Winter, E. Stathopoulos, F-M Chen, J. W. Parker, C. R. Taylor, Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnost ic and immunotherapeutic potential, Cancer Res. 47:830–840 (1987).PubMedGoogle Scholar
  12. 12.
    C. F. Meares, M. J. McCall, D. T. Reardan, D. A. Goodwin, C. I. Diamanti, M. McTigue, Conjugation of antibodies with bifunctional chelating agents, Anal. Biochem. 142:68–78 (1984).PubMedCrossRefGoogle Scholar
  13. 13.
    M. K. Moi, C. F. Meares, M. J. McCall, W. C. Cole, S. J. DeNardo, Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent, Anal. Biochem. 148:249–253 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    S. V. Deshpande, S. J. DeNardo, C. F. Meares, M. K. Moi, M. J. McCall, G. L. DeNardo, Design of therapeutic Copper-67 labeled monoclonal antibodies, J. Nuc. Med. 27:1041 (1986).Google Scholar
  15. 15.
    S. V. Deshpande, S. J. DeNardo, C. F. Meares, M. J. McCall, G. P. Adams, M. K. Moi, G. L. DeNardo, Copper TETA Lym-1 labeling and biodistribution, J. Nuc. Med. 1987 (in press).Google Scholar
  16. 16.
    R. R. Traut, A. Bollen, T. T. Sun, Methyl 4-mercaptobuterimi-date as a cleavable cross-linking reagent and its applications to the E. Coli 30s ribosome, Biochemistry 12:3266–3273 (1973).PubMedCrossRefGoogle Scholar
  17. 17.
    G. L. DeNardo, W. C. Young, S. J. DeNardo, J-S Peng, S. L. Mills, Urinary metabolites after injection of monoclonal antibodies (MAb) or fibrinogen (F) radioiodinated with a small and large number of iodine atoms, J. Nuc. Med. 27:958 (1986).Google Scholar
  18. 18.
    M. G. Rosenblum, J. L. Murray, T. P. Haynie, H. J. Glenn, M. F. Jahns, R. S. Benjamin, J. M. Frincke, D. J. Carlo, E. M. Hersh, Pharmacokinetics of 111-In-labeled Anti-p97 monoclonal antibody in patients with metastatic malignant melanoma, Cancer Res. 45, 2382–2386 (1985).PubMedGoogle Scholar
  19. 19.
    C. A. Owen Jr: Metabolism of radiocopper (Cu-64) in the rat, Amer J. Physiol. 209:900–904 (1965).PubMedGoogle Scholar
  20. 20.
    S. J. DeNardo, G. L. DeNardo, L. F. O’Grady, D. J. Macey, S. L. Mills, A. L. Epstein, J-S. Peng, J. P. McGahan, Treatment of a patient with B cell lymphoma with I-131 Lym-1 monoclonal antibodies, Intl. J. Biol. Markers 2:1987 (in press).Google Scholar
  21. 21.
    S. J. DeNardo, G. L. DeNardo, L. F. O’Grady, Radioimmunotherapy of patients with B cell lymphoma using I-131 Lym-1 monoclonal antibody, J. Nuc. Med. 27:903 (1986) (Abstract).Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • S. J. DeNardo
    • 1
  • G. L. DeNardo
    • 1
  • S. V. Deshpande
    • 1
  • G. P. Adams
    • 1
  • D. J. Macey
    • 1
  • S. L. Mills
    • 1
  • A. L. Epstein
    • 1
  • C. F. Meares
    • 1
  1. 1.Medical CenterUniversity of California, DavisSacramentoUSA

Personalised recommendations